|
|
|
| Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer |
| Stefan Heinrich ∗ |
General, Visceral and Transplantation Surgery, University Hospital of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany
∗ Corresponding author.
E-mail address: stefan.heinrich@unimedizin-mainz.de (S. Heinrich). |
|
|
|
|
Abstract Surgery is the standard therapy for pancreatic ductal adenocarcinoma (PDAC). After the dramatic decline of operative mortality over the past decades, the indications for pancreas resections have been continuously extended: currently resections of the portal/superior mesenteric vein are considered standard by many centers, and even arterial resections are under debate. Following these changes, different expert groups have defined resectability criteria containing a grey zone (“borderline resectable disease”) of tumors, which may be technically resectable with appropriate surgical expertise, but resection inherits an increased risk of an R1-resection [1].
|
|
|
|
|
|
|
|
|
2019, Vol. 18 
